Sectors

AMGN
Amgen Inc.
350.38
1 x 351.67
1 x 351.44
bid
ask
+
3.37
0.97%
01:38 PM
timesize
Ytd 7.05%
1y 26.27%
346.00
day range
353.19
271.18
52 week range
388.16
Open 348.00 Prev Close 347.01 Low 346.00 High 353.19 Mkt Cap 189.00B
Vol 751.21K Avg Vol 2.75M EPS 14.37 P/E 24.37 Forward P/E 14.68
Beta 0.42 Short Ratio 4.38 Inst. Own 85.22% Dividend 10.08 Div Yield 2.99
Ex Div Date 05-15 Earning 08-04 50-d Avg 339.96 200-d Avg 332.51 1yr Est 352.77
Earning
Date For Estimate Reported Surprise surprise %
2026-04-30 2026-03 4.73 5.15 0.42 8.88%
2026-02-03 2025-12 4.76 5.29 0.53 11.13%
2025-11-04 2025-09 5 5.64 0.64 12.80%
2025-08-05 2025-06 5.26 6.02 0.76 14.45%
2025-05-01 2025-03 4.16 4.9 0.74 17.79%
2025-02-04 2024-12 5.03 5.31 0.28 5.57%
Upgrade / Downgrade
Date Firm Action From To
2026-06-16 Mizuho Upgrade Neutral Neutral
2026-06-10 Morgan Stanley Upgrade Equal-Weight Equal-Weight
2026-05-14 Piper Sandler Upgrade Overweight Overweight
2026-05-04 Guggenheim Upgrade Neutral Neutral
2026-05-01 Truist Securities Upgrade Hold Hold
2026-04-21 Canaccord Genuity Upgrade Hold
Profile
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Insider Holder
Date Name Relation Quantity Description
2026-05-04 BRADNER JAMES E. Officer 30.46K Stock Award(Grant)
2026-05-04 BRADWAY ROBERT A Chief Executive Officer 657.30K Stock Award(Grant)
2026-05-18 ECKERT ROBERT ANDREW Director 26.25K Stock Award(Grant)
2026-05-04 GORDON MURDO Officer 51.84K Stock Award(Grant)
2026-05-04 GRAHAM JONATHAN P General Counsel 40.21K Stock Award(Grant)
2026-05-04 GRIFFITH PETER H. Chief Financial Officer 50.71K Stock Award(Grant)
Institution Ownership
Report Date Organization Position Value Percentage
2026-03-30 Blackrock Inc. 47.10M 16.34B 8.73%
2026-03-30 Vanguard Capital Management LLC 35.01M 12.15B 6.49%
2026-03-30 State Street Corporation 30.55M 10.60B 5.66%
2026-03-30 Capital World Investors 29.29M 10.16B 5.43%
2026-03-30 Morgan Stanley 15.84M 5.50B 2.93%
2026-03-30 Geode Capital Management, LLC 15.43M 5.35B 2.86%
Fund Ownership
Report Date Organization Position Value Percentage
2026-03-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 17.12M 5.94B 3.17%
2026-03-30 VANGUARD INDEX FUNDS-Vanguard 500 Index Fund 13.68M 4.75B 2.54%
2026-05-30 Invesco QQQ Trust, Series 1 11.68M 4.05B 2.16%
2026-02-27 SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF 8.70M 3.02B 1.61%
2026-03-30 WASHINGTON MUTUAL INVESTORS FUND 8.63M 2.99B 1.60%
2026-03-30 Income Fund of America 7.61M 2.64B 1.41%
Dividend
Dividend Date
2.52 2026-05-15
2.52 2026-02-13
2.38 2025-11-21
2.38 2025-08-22
2.38 2025-05-16
2.38 2025-02-14
Split
Split Date
2 : 1 1999-11-22
2 : 1 1999-03-01
2 : 1 1995-08-16
3 : 1 1991-09-11
2 : 1 1990-08-13